5h agoSeeking AlphaNEUTRAL 50Earnings
Here are the major earnings before the open Thursday
Major earnings expected before the bell on Thursday include:Altria Group (MO)Eli Lilly and Company (LLY)Merck & Co.
Why Is ELI LILLY AND CO (LLY) Stock Moving Today?
By the Top Tier Newswire AI Desk · September 4, 2026 at 3:11 PM ET · reviewed against 29 wire stories
ELI LILLY AND CO (LLY) is drawing unusual attention today. Our newswire has captured 29 stories on LLY across 15 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Eli Lilly (LLY) shares are moving lower today, down 1.6% as of 4:15 PM ET, amid a combination of recent insider selling and a broader pullback after a strong 52-week high. The stock opened at $1157.80 but has since fallen to $1140.69, with volume at 0.7 million shares, below its 3-month average. The decline comes after a recent wave of bullish commentary and strategic acquisitions that had pushed the stock to record levels.
What Happened
Eli Lilly’s stock has been underpinned by a string of high-profile deals and strong performance from its weight-loss drugs, including Mounjaro and Zepbound. The company announced its 13th acquisition of the year, a $2.88 billion deal for Merida Biosciences to expand its autoimmune and immunotherapy portfolio. This follows a $60 million Series B financing in Superluminal Medicines, in which Lilly participated, and a $8.6 million milestone payment for Nxera Pharma’s progress in obesity-related treatments. JPMorgan Chase recently raised its stance on LLY, citing accelerating sales of its GLP-1 drugs, while The Motley Fool highlighted the company’s ongoing momentum. Despite these developments, the stock has seen a pullback after hitting a 52-week high of $1292.65.
What The Data Shows
The stock has declined 5.2% over the last eight sessions, from $1206.96 to $1143.66. Insider selling has been notable, with three executives, Patrik Jonsson, Donald Zakrowski, and Anat Hakim, selling shares between August 7 and August 18. Congressional trades also show recent activity, with Rep. Dan Newhouse and Rep. Michael Rulli selling between $1,001 and $15,000 of LLY stock in July. Volume today remains subdued at 0.7 million shares, or 0.2 times the 3-month average, suggesting limited follow-through from buyers. The stock is trading at a P/E of 38.9, with a market cap of $1.03 trillion and a beta of 0.51.
What To Watch
The company has no earnings report scheduled in the near term. Investors will likely monitor the breadth of analyst coverage and any further developments in the company’s acquisition strategy.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
LLY by the numbers
7 sessions: +5.85%Coverage: 29 stories / 15 sourcesAI sentiment: 58/100 (bullish)Mkt cap: $1.03TP/E: 38.952w: $712.05 to $1292.65
The headlines behind the move
7h agoFidelity NewsBULLISH 58General
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and the State Street Health Care Select Sector SPDR ETF adding 0.4%. The iShares Biotechnology ETF rose 1.4%. In corporate news, Eli Lilly (LLY.NaE) said data from a phase 3 head-to-head trial showed retatrutide delivered greater A1C reduction and "substantially" more weight loss than Novo Nordisk's (NVO.NaE) injectable ...
7h ago24/7 Wall St.BEARISH 38General
16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage
Employers are quietly reconsidering who foots the bill for GLP-1 weight-loss drugs, and the fallout hits Eli Lilly and Novo Nordisk very differently heading into earnings week.
8h agoThe FlyBEARISH 42Earnings
Novo Stock Nvo Falls After Another Head To Head Obesity Trial Loss To Eli Lilly
9h agoFidelity NewsBULLISH 58General
Sector Update: Healthcare Stocks Advance Wednesday Afternoon
Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and the State Street Health Care Select Sector SPDR ETF adding 0.4%. The iShares Biotechnology ETF climbed up 1.9%. In corporate news, Eli Lilly (LLY.NaE) said data from a phase 3 head-to-head trial showed retatrutide delivered greater A1C reduction and "substantially" more weight loss than Novo Nordisk's (NVO.NaE) injectable Ozempi...
9h agoQuartzBULLISH 74Product/PR
Lilly's retatrutide more than doubled Ozempic weight loss in trial
10h agoGuruFocusNEUTRAL 52Earnings
Merck (MRK) and Eli Lilly Set to Report Q3 Earnings Amid Market Anticipation
On October 28, 2026, Merck & Co Inc (NYSE: MRK) is poised to release its third-quarter earnings on October 29, drawing investor attention not only for its opera
11h agoSeeking AlphaBULLISH 62General
Midday Pulse: S&P 500 top intraday gainers
S&P 500 top intraday gainers: Cboe, Eli Lilly, Bristol-Myers, AbbVie & Gilead—see the biggest movers as markets digest the latest CPI report.
11h agoTipRanksBEARISH 44General
Eli Lilly’s (LLY) Head of International Business Retires
Pharmaceutical giant Eli Lilly ($LLY) has announced that Patrik Jonsson, executive vice president and president of the company’s international business, will retir...
11h agoBusiness InsiderNEUTRAL 50Earnings
Pharma giants Merck, Eli Lilly face earnings health check
Preview Merck and Eli Lilly Q3 earnings: Keytruda risks, GLP-1 growth, guidance outlook, and key drugs to watch.
Frequently asked questions
Why is LLY stock moving today?
ELI LILLY AND CO (LLY) is drawing unusual attention today. Our newswire has captured 29 stories on LLY across 15 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100). The most recent driver: "Here are the major earnings before the open Thursday" (Seeking Alpha).
Is LLY a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of LLY coverage reads 58/100 over 29 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is AXGN up today (+31.47%)
- Why is GMAB up today (+28.25%)
- Why is REPL up today (+23.07%)
- Why is FFIV down today (-20.43%)
- Why is RAPP down today (-18.30%)
- Why is LSTR down today (-17.76%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on LLY: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier LLY move explainers: 2026-09-04 · 2026-09-02 · 2026-08-31